Cassava Sciences Message Board


What's the Strategy in the U.S. for Neovasc's Reducer?

7 months ago

Neovasc (Nasdaq: NVCN) is a medical device company primarily known for Reducer, which is a minimally invasive device that helps treat patients with refractory angina. The device has been approved in Europe

What's the Strategy in the U.S. for Neovasc's Reducer?

7 months ago

Neovasc (Nasdaq: NVCN) is a medical device company primarily known for Reducer, which is a minimally invasive device that helps treat patients with refractory angina. The device has been approved in Europe

​Cassava Sciences Phase 2a Clinical Data in Alzheimer’s Disease

8 months ago

Exciting year for SAVA -

Cassava Sciences is now evaluating PTI-125 in a confirmatory Phase 2b study. This blinded, randomized, placebo-controlled, multi-dose study is enrolling approximately 60 patients with mild-to-moderate Alzheimer’s disease. The primary endpoint is improvement in biomarkers of Alzheimer’s disease from baseline to Day 28. Top-line study results are expected in 2020.

“Today’s data milestone is exciting because it provides additional support for the clinical benef…

Loading...